Galactoflavin is a synthetic compound and riboflavin (vitamin B2) antagonist and antimetabolite. It is a biochemical tool used primarily in research to induce riboflavin deficiency in animal models and humans. It is structurally similar to riboflavin, where the ribose-derived side chain is replaced by a galactose-derived group.
Galactoflavin's chemical formula is C18H22N4O7 and has a molecular weight of 406.40 g/mol. Galactoflavin appears as yellow crystals that decompose at 260 °C and exhibit absorption maxima at 223, 267, 370, and 445 nm.[1] It displays yellow-green fluorescence in water.[1]
Biological activity
As a riboflavin analog, galactoflavin competes with riboflavin in metabolic pathways, leading to depletion of riboflavin-containing coenzymes such as flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) in tissues such as liver and kidney.[2] This antagonism results in riboflavin deficiency symptoms that are reversible with excess riboflavin supplementation. In rats, galactoflavin feeding reduces flavin content in mitochondria and affects oxidative phosphorylation.[3]
The antiriboflavin effect of galactoflavin was first demonstrated in 1945 and was found to produce riboflavin deficiency in rats reversible by excess riboflavin.[4]
Galactoflavin has been employed to study the effects of riboflavin deficiency on growth, enzyme activity, and congenital malformations.[6][7][8] In pregnant rats, it induces multiple congenital abnormalities in embryos, including cardiovascular defects and hydrocephalus, by disrupting terminal electron transport systems. It has also been investigated for potential antitumor effects due to its ability to cause regression of tumors in rodents through riboflavin deficiency.
In mice, dietary galactoflavin affects hepatocyte ultrastructure.[9] It impairs adrenal ascorbic acid response to stress in rats.[10]
References
12Merck Index (11thed.), p.678, 4239. Galactoflavin
↑Beyer, Robert E.; Lamberg, Stanley L.; Neyman, M. Arthur (1961). "The Effect of Riboflavin Deficiency and Galactoflavin Feeding on Oxidative Phosphorylation and Related Reactions in Rat Liver Mitochondria". Canadian Journal of Biochemistry and Physiology. 39: 73–88. doi:10.1139/o61-009.
↑Nelson, Marjorie M.; Baird, Catherine D.C.; Wright, Howard V.; Evans, Herbert M. (1956). "Multiple Congenital Abnormalities in the Rat Resulting from Riboflavin Deficiency Induced by the Antimetabolite Galactoflavin". The Journal of Nutrition. 58: 125–134. doi:10.1093/jn/58.1.125. PMID13286747.
↑Aksu, Oguz; MacKler, Bruce; Shepard, Thomas H.; Lemire, Ronald J. (1968). "Studies of the development of congenital anomalies in embryos of riboflavin-deficient, galactoflavin fed rats. II. Role of the terminal electron transport systems". Teratology. 1 (1): 93–102. doi:10.1002/tera.1420010110. PMID4302703.
↑Lane, M.; Brindley, C. O. (1964). "Laboratory and Clinical Studies with the Riboflavin Antagonist, Galactoflavin". Experimental Biology and Medicine. 116: 57–61. doi:10.3181/00379727-116-29158. PMID14200132.
↑Tandler, Bernard; Hoppel, Charles L. (1974). "Ultrastructural effects of dietary galactoflavin on mouse hepatocytes". Experimental and Molecular Pathology. 21 (1): 88–101. doi:10.1016/0014-4800(74)90081-1. PMID4370691.
↑Slater, Grant G. (1959). "INFLUENCE OF GALACTOFLAVIN AND INANITION ON THE ADRENAL ASCORBIC ACID RESPONSE TO STRESS IN RATS1". Endocrinology. 65 (5): 731–738. doi:10.1210/endo-65-5-731. PMID13831613.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.